4.4 Article

Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus plus Patients Treated with Direct-Acting Antiviral Agents

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy

Mizuki Nishibatake Kinoshita et al.

JOURNAL OF HEPATOLOGY (2019)

Article Gastroenterology & Hepatology

HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma

George N. Ioannou et al.

JOURNAL OF HEPATOLOGY (2018)

Article Gastroenterology & Hepatology

Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012

Donna L. White et al.

GASTROENTEROLOGY (2017)

Article Gastroenterology & Hepatology

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Fasiha Kanwal et al.

GASTROENTEROLOGY (2017)

Letter Gastroenterology & Hepatology

Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study

Philippe Kolly et al.

JOURNAL OF HEPATOLOGY (2017)

Article Gastroenterology & Hepatology

Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma

Lauren A. Beste et al.

JOURNAL OF HEPATOLOGY (2017)

Article Gastroenterology & Hepatology

Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population

Sahil Mittal et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)

Article Oncology

Cancer statistics, 2013

Rebecca Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2013)

Review Medicine, General & Internal

CURRENT CONCEPTS Hepatocellular Carcinoma

Hashem B. El-Serag

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Article Medicine, General & Internal

The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update

H El-Serag et al.

ANNALS OF INTERNAL MEDICINE (2003)